RUN just reported Q1 2026 numbers that cleared the bar — earnings per share of $0.62 versus a consensus estimate of -$0.01, on revenue of $722 million against a $682 million forecast. The result is a clean beat on both lines. Yet the stock closed Tuesday up only 6%, and initial after-hours reports describe the stock sliding despite a bullish upgrade. That gap between the fundamental delivery and the market's muted response is where the most interesting tension on this name sits right now.
Short interest at 22.5% of the free float is high by any measure, but the directional story has shifted. Shorts were running north of 24% as recently as mid-April, and the position has quietly unwound by roughly 1.7 percentage points over the past three weeks. The move has been gradual — no single-day capitulation, just steady covering from late April into the first week of May. Cost to borrow sits around 0.46%, well off recent highs and down roughly 18% on the week, consistent with covering rather than fresh building. Availability in the lending market remains ample, with borrow demand having eased from peaks around the April 6-8 tariff volatility window. The ORTEX short score of 60.5 is elevated but has drifted lower from 62.6 at end of April. None of this points to a crowded exit — the unwind has been orderly.
Options are flashing a distinctly bullish tilt heading into results. The put/call ratio has dropped to 0.70, almost two standard deviations below its 20-day average of 0.84 — the most call-heavy positioning of the past year relative to that average. The 52-week range on the PCR runs from 0.50 to 1.23, so the current reading is pushing toward the bullish extreme rather than hitting it. The shift has been consistent over the past two weeks, with the ratio declining almost every day from the high-0.80s and low-0.90s seen through most of March and early April. Options traders were clearly anticipating the beat before the number landed.
The analyst community has spent the past six weeks cutting targets while mostly holding buy ratings. Goldman Sachs lowered to $20 from $24 in mid-April, Citigroup moved to $20 from $26 on April 21, and JP Morgan trimmed to $22 from $25 on April 16, all while maintaining positive ratings. The consensus mean target around $19.67 compares to a close of $13.46, implying roughly 46% return potential — a wide gap that reflects how far the stock has fallen from favour rather than unbridled optimism. GLJ Research remains an outlier, reiterating a $4.63 Sell. The factor score picture adds nuance: EPS momentum over the past 30 days ranks in the 95th percentile — the company has been beating forward estimates — but 90-day EPS momentum is near the bottom of the universe at the 8th percentile, and the forward EPS growth rank is even lower at 2nd. Valuation offers some support; the stock trades at 0.82x book value and an EV/EBITDA of 23.6x, with the P/E multiple easing from higher levels over the past month.
Insider activity tells a more cautious story. On April 6, the CEO, CFO, President, and HR Director all sold shares simultaneously — a coordinated wave that totalled over $7 million in aggregate. The founder Lynn Jurich sold another 50,000 shares on April 1 and again on May 1. Net insider selling over the 90-day window runs to approximately 728,000 shares and roughly $9.6 million in value. These transactions appear to follow pre-scheduled plans, given their regularity, but the cluster of C-suite selling on a single day in early April is notable. Institutional holders have been more stable: BlackRock added 1.4 million shares as of April 30, and State Street and Geode both added modestly. The base of passive ownership looks solid.
The one historical data point worth noting: the last earnings print — Q4 2025 in February — delivered a -32% one-day reaction and a -40% move over the following five days. That print clearly drove the April short-covering narrative, as some bears reassessed after the carnage. The Q1 beat is a materially different setup. With the next earnings event scheduled for May 28, the focus now turns to whether management's updated guidance — and any commentary on the July 2026 legislative milestone that underpins the bull case — is enough to keep the gradual short-covering trend intact.
See the live data behind this article on ORTEX.
Open RUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
